All the news Showing 6 of 36 articles from: Hepatocellular carcinoma (HCC)Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Long-term tenofovir reduces liver cancer risk in people with hepatitis B Liz Highleyman / 27 April 2013 Long-term treatment with tenofovir (Viread) lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about five years, according to a ... Liver cancer has a more aggressive disease course in HIV-positive people co-infected with viral hepatitis Michael Carter / 18 December 2012 Co-infection with HIV and viral hepatitis is associated with a more aggressive disease course for liver cancer, according to research conducted in London and presented to the recent EASL Monothematic Conference: HIV and ... Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising Liz Highleyman / 05 December 2012 The investigational cancer drug brivanib did not significantly increase survival for people with hepatocellular carcinoma over existing standard therapy, researchers reported at the recent Liver Meeting 2012, the 63rd Annual Meeting of ... Nucleoside analogues reduce hepatitis B liver cancer risk Liz Highleyman / 29 November 2012 Treatment of chronic hepatitis B with nucleoside analogues including lamivudine (Epivir) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection surgery, according to data presented ... Dramatic increase in incidence of liver cancer in HIV-positive people with viral hepatitis Michael Carter / 29 October 2012 Incidence of liver cancer among people with HIV has increased dramatically over the past decade, Spanish investigators report in the online edition of Clinical Infectious Diseases. All the cases involved individuals with ... Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity Liz Highleyman / 30 April 2012 The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumour activity, researchers reported at the 47th ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive